Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Liposarcoma × olaparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 34 Breast Neoplasms 26 Triple Negative Breast Neoplasms 17 Prostatic Neoplasms 17 Fallopian Tube Neoplasms 11 Neoplasms 9 Pancreatic Neoplasms 7 Fanconi Anemia, Complementation Group D1 7 Endometrial Neoplasms 7 Glioma 6 Carcinoma, Ovarian Epithelial 6 Stomach Neoplasms 5 Small Cell Lung Carcinoma 5 Sarcoma 5 Neoplasm Metastasis 5 Cholangiocarcinoma 5 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Lymphoma, Non-Hodgkin 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Osteosarcoma 3 Lung Neoplasms 3 Glioblastoma 3 Colorectal Neoplasms 3 Carcinosarcoma 3 Carcinoma, Renal Cell 3 Wilms Tumor 2

Interventions

Doxorubicin 6 Trabectedin 5 pazopanib 4 Radiotherapy 4 ribociclib 3 pembrolizumab 3 palbociclib 3 Gemcitabine 3 brostallicin 2 Sunitinib 2 Radiation Dose Hypofractionation 2 Radiation 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 Ipilimumab 2 Immunoglobulin G 2 Imatinib Mesylate 2 Ifosfamide 2 Docetaxel 2 Dexamethasone 2 CTLA-4 Antigen 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zimberelimab 1 temsirolimus 1 tanespimycin 1 talimogene laherparepvec 1 sotigalimab 1 soblidotin 1 sitravatinib 1 saracatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06116578 2025-12-01

NeoSarc

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Withdrawn

Liposarcoma, Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡